Hematology

Northfield Laboratories reports fiscal 2002 third quarter results

Published in Blood Weekly, May 23rd, 2002

Northfield Laboratories, Inc., (NFLD), a developer of an oxygen-carrying blood substitute for trauma and elective surgery situations, reported a loss as anticipated of $0.18 per basic share for its third fiscal quarter ended February 28, 2002.

As a developmental stage company, Northfield has no revenues.

For the third quarter, Northfield reported a loss of $2.6 million, or $0.18 cents per basic share compared with a loss of $2.6 million, or $0.18 cents per basic share, in the year earlier period. For the latest 9 months, net loss was $7.9 million, or $0.56 cents per basic share compared with a loss of $7.4 million, or $0.52 cents per basic share, in...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2002-05-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry